Education
About Us
Working with TipRanks
Follow Us
Terns Pharmaceuticals (TERN)
NASDAQ:TERN
Total Valuation
Terns Pharmaceuticals has a market cap or net worth of $592.45M. The enterprise value is $27.26M.
Market Cap$592.45M
Enterprise Value$27.26M
Share Statistics
Terns Pharmaceuticals has 87,511,050 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding87,511,050
Owned by Insiders2.51%
Owned by Institutions0.53%
Financial Efficiency
Terns Pharmaceuticals’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -29.30%.
Return on Equity (ROE)-0.26
Return on Assets (ROA)-0.24
Return on Invested Capital (ROIC)-29.30%
Return on Capital Employed (ROCE)-0.29
Revenue Per Employee0.00
Profits Per Employee-1.51M
Employee Count59
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Terns Pharmaceuticals is ―. Terns Pharmaceuticals’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value1.27
Price to FCF―
Price to Operating Cash Flow-7.99
PEG Ratio―
Income Statement
In the last 12 months, Terns Pharmaceuticals had revenue of 0.00 and earned -88.85M in profits. Earnings per share was -1.12.
Revenue0.00
Gross Profit0.00
Operating Income-101.87M
Pretax Income-88.59M
Net Income-88.85M
EBITDA-87.70M
Earnings Per Share (EPS)-1.12
Cash Flow
In the last 12 months, operating cash flow was -74.36M and capital expenditures 0.00, giving a free cash flow of -74.36M billion.
Operating Cash Flow-74.36M
Free Cash Flow-74.36M
Free Cash Flow per Share-0.85
Dividends & Yields
Terns Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.86
52-Week Price Change-2.76%
50-Day Moving Average4.98
200-Day Moving Average4.56
Relative Strength Index (RSI)73.83
Average Volume (3m)1.01M
Important Dates
Terns Pharmaceuticals upcoming earnings date is Nov 18, 2025, After Close (Confirmed).
Last Earnings DateAug 5, 2025
Next Earnings DateNov 18, 2025
Ex-Dividend Date―
Financial Position
Terns Pharmaceuticals as a current ratio of 23.14, with Debt / Equity ratio of 0.37%
Current Ratio23.14
Quick Ratio23.14
Debt to Market Cap<0.01
Net Debt to EBITDA1.83
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Terns Pharmaceuticals has paid 260.00K in taxes.
Income Tax260.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Terns Pharmaceuticals EV to EBITDA ratio is -3.20, with an EV/FCF ratio of -4.00.
EV to Sales0.00
EV to EBITDA-3.20
EV to Free Cash Flow-4.00
EV to Operating Cash Flow-4.00
Balance Sheet
Terns Pharmaceuticals has $315.44M in cash and marketable securities with $1.13M in debt, giving a net cash position of -$314.31M billion.
Cash & Marketable Securities$315.44M
Total Debt$1.13M
Net Cash-$314.31M
Net Cash Per Share-$3.59
Tangible Book Value Per Share$4.35
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Terns Pharmaceuticals is $17.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$17.00
Price Target Upside151.11% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast20.37%